Back

Time to go R2-D2 with molecular bio diagnostics—automating lab life 😄

Why qPCR & Phenotypic Testing Must Be Displaced? – Part III This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren

Why qPCR & Phenotypic Testing Must Be Displaced – Part II If you ever want to understand the scale of a problem, look at how much it costs. Tuberculosis alone costs India, Africa, and Brazil 27 trillion INR a year in lost productivity and healthcare

Can Sequencing replace traditional diagnostics in India? Traditional diagnostics are slow. Culture and antibiotic resistance tests take days or even weeks to deliver results. This can be detrimental for patients suffering from sepsis or fever of unk

From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane. 💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr. 🔬 Their Truenat platform, is a battery-power

🚨 The magic number: ₹800 Cr ⸻ VCs invest in businesses that can be big enough to return their entire fund. To get VCs interested, your startup must at least have the potential to reach ₹800 Cr+ in annual revenue or ₹8,000 Cr+ in market cap (assumi

A genetic testing company is pitching on Shark Tank tomorrow—possibly the first biotech startup to enter the tank! 🦈 <> 🧬 Curious to see how the sharks react to DNA sequencing and whether they’ll bite. Is the product legit? Will they challenge th

Why qPCR & phenotypic testing must be displaced? - Part I The Problem: Infectious diseases remain a significant public health threat. Particularly, in low and middle-income countries (LMICs), such as India. €300 Billion / 27 Trillion INR! {1} - Th